Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 5,051 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Recruiting Phase 1Phase 2 Interventional

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126
View directory record Official record
Conditions
NSCLC
Interventions
EP0031, Platinum chemotherapy, Pemetrexed
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Terminated Phase 3 Interventional Results available

Empiric Therapy of Mucopurulent Cervicitis (MPC)

NCT01072136
View directory record Official record
Conditions
Vaginitis Bacterial, Cervicitis
Interventions
Placebo, Azithromycin, Cefixime
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Birmingham, Alabama • Torrance, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 30, 2026, 7:53 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect and Tolerance of Musclin™ (Thymol) in Healthy Subjects

NCT03767504
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Thymol
Dietary Supplement
Lead sponsor
Innovus Pharmaceuticals, Inc.
Industry
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

NCT01706315
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 4 Interventional

The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs

NCT00002425
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Lipoic Acid as a Treatment for Acute Optic Neuritis

NCT01294176
View directory record Official record
Conditions
Optic Neuritis
Interventions
Lipoic Acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 4 Interventional

Pregabalin (Lyrica) for the Treatment of Essential Tremor

NCT00584376
View directory record Official record
Conditions
Essential Tremor
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Oct 30, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07259317
View directory record Official record
Conditions
Adenocarcinoma, Carcinoma, Pancreatic Ductal
Interventions
Relacorilant, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

NCT00094458
View directory record Official record
Conditions
Crohn Disease
Interventions
infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps
Biological · Other · Drug
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
21 Years to 99 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression

NCT00903448
View directory record Official record
Conditions
Healthy
Interventions
Prilosec OTC (omeprazole-magnesium), Prevacid
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 31, 2010 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 4 Interventional

QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia

NCT00150826
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Quinapril, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

NCT03341078
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Ibudilast, Placebo Oral Tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Withdrawn Phase 4 Interventional

Guanfacine Extended Release and Mindfulness Skills Therapy

NCT03258476
View directory record Official record
Conditions
Stress Disorder
Interventions
Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo
Drug · Behavioral
Lead sponsor
UConn Health
Other
Eligibility
10 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 30, 2026, 7:53 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052
View directory record Official record
Conditions
Differentiated Thyroid Cancer (DTC)
Interventions
Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate the Use of the Foundation Pain Index and the Nutritional Supplement BioPlete™ in Adults With Chronic Pain

NCT05278533
View directory record Official record
Conditions
Chronic Pain
Interventions
BioPlete™ Advanced Formula, Placebo
Dietary Supplement
Lead sponsor
Ethos Research & Development
Industry
Eligibility
30 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Tampa, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 7:53 PM EDT
Recruiting Phase 1 Interventional

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

NCT05762952
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)

NCT02711852
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Duvelisib
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 30, 2026, 7:53 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

NCT03094832
View directory record Official record
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
Interventions
Miransertib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

NCT04375878
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
MS1819, Porcine PERT
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

NCT02395978
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PDC-1421 Capsule, placebo
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
20 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer

NCT00600535
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Stage 1 Group 1: abiraterone acetate, Stage 1 Group 2: abiraterone acetate, Stage 2: abiraterone acetate, Stage 3: abiraterone acetate, Stage 3: glucocorticoid, Stage 4: abiraterone acetate, Stage 4: glucocorticoid
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508
View directory record Official record
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing Two Coenzyme Q10 Products in Men and Women

NCT07530250
View directory record Official record
Conditions
CoQ10 Blood Levels
Interventions
high absorption CoQ10 product, standard CoQ10 product
Dietary Supplement
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Green Tea and Reduction of Breast Cancer Risk

NCT00917735
View directory record Official record
Conditions
Breast Cancer
Interventions
Green tea extract supplement, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
1,075 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
5
States / cities
Edina, Minnesota • Maple Grove, Minnesota • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 30, 2026, 7:53 PM EDT